AMD Risk Assessment
AMD Risk Assessment Age-related Macular Degeneration (AMD) is a leading cause of vision loss in older adults. The risk of an individual being diagnosed with AMD can be related to a variety of risk factors. The quiz below can help illustrate the relationship between AMD and those risk factors. It takes 2 minutes. AMD Risk…
Read MoreL-DOPA Association with Reduced Detection of New-Onset GA
Source: Eye and Vision, 2024 Background Geographic atrophy (GA) is a significant cause of vision loss in patients with age-related macular degeneration (AMD). Current treatments are limited to anti-complement drugs, which have limited efficacy to delay progression with significant risk of complications. Levodopa (L-DOPA) is a byproduct of melanin synthesis that is associated with reduced…
Read MoreAdditional Patents Licensed for Use
(a) United States Patent Number U.S. 11,969,401 entitled •compositions and Methods for Treating or Limiting Development of Age-Related Macular Degeneration· issued on April 30, 2024 {ARIZONA Ref No. UA19-094); and (b) United States Patent Number U.S. 9,173,862 entitled “Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration” issued on November 3,…
Read MoreWhat are anti-VEGF injections?
The most common treatment doctors use to slow vision loss from wet AMD is called anti-VEGF injections. These medicines help stop bleeding and leaking from blood vessels in the back of your eye. Most people with wet AMD will get anti-VEGF injections as their only treatment. When you get this treatment, your doctor will: Anti-VEGF…
Read MoreRole of L-DOPA in Prevention of GA
Source: Eye and Vision, 2024 Background Geographic atrophy (GA) is a significant cause of vision loss in patients with age-related macular degeneration (AMD). Current treatments are limited to anti-complement drugs, which have limited efficacy to delay progression with significant risk of complications. Levodopa (L-DOPA) is a byproduct of melanin synthesis that is associated with reduced…
Read MoreUS Patent 9,173,862 for MaculaPM™
METHODS AND COMPOSITIONS FOR TREATING AND IDENTIFYING COMPOUNDS TO TREAT AGE-RELATED MACULAR DEGENERATION
Read MoreUS Patent 9,861,600 for MaculaPM™
METHODS AND COMPOSITIONS FOR TREATING AND IDENTIFYING COMPOUNDS TO TREAT AGE-RELATED MACULAR DEGENERATION TREATMENT
Read MoreUS Patent 11,969,401 for MaculaPM™
COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION
Read More
